RHUMBLINE ADVISERS - INVIVO THERAPEUTICS HLDGS CO ownership

INVIVO THERAPEUTICS HLDGS CO's ticker is NVIV and the CUSIP is 46186M209. A total of 63 filers reported holding INVIVO THERAPEUTICS HLDGS CO in Q2 2016. The put-call ratio across all filers is 0.32 and the average weighting 0.0%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of INVIVO THERAPEUTICS HLDGS CO
ValueSharesWeighting
Q1 2017$140,000
+0.7%
34,599
+4.6%
0.00%
Q4 2016$139,000
-47.3%
33,090
-14.7%
0.00%
-100.0%
Q3 2016$264,000
+18.4%
38,798
+0.8%
0.00%0.0%
Q2 2016$223,000
+26.7%
38,498
+52.7%
0.00%0.0%
Q1 2016$176,000
-3.3%
25,2140.0%0.00%0.0%
Q4 2015$182,000
-8.1%
25,214
+10.0%
0.00%0.0%
Q3 2015$198,000
-44.1%
22,924
+4.6%
0.00%0.0%
Q2 2015$354,00021,9150.00%
Other shareholders
INVIVO THERAPEUTICS HLDGS CO shareholders Q2 2016
NameSharesValueWeighting ↓
IMS Capital Management 324,148$1,874,0002.19%
SABBY MANAGEMENT, LLC 580,343$3,354,0000.18%
WELCH & FORBES LLC 979,554$5,661,0000.17%
Hayek Kallen Investment Management 12,015$69,0000.05%
Indiana Trust & Investment Management CO 13,250$77,0000.04%
BOSTON FINANCIAL MANGEMENT LLC 74,175$429,0000.04%
HYMAN CHARLES D 32,100$186,0000.03%
Baker Brothers Advisors 400,000$2,312,0000.02%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 90,650$524,0000.01%
Edge Wealth Management LLC 3,000$17,0000.01%
View complete list of INVIVO THERAPEUTICS HLDGS CO shareholders